Taysha Gene Therapies, Inc. 4

Nagendran Sukumar, President and Head of R&D of Taysha Gene Therapies, Inc., sold 200,000 shares of common stock at about $6.24 per share under a Rule 10b5-1 plan.

On July 10, 2026, Nagendran Sukumar, President and Head of R&D of Taysha Gene Therapies, Inc., sold 200,000 shares of the company’s common stock at a weighted average price of approximately $6.24 per share, for proceeds of about $1.25 million, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on June 11, 2025. The shares were sold in multiple transactions within a price range of $5.99 to $6.52 per share. Following this transaction, Sukumar’s direct ownership stands at 936,410 shares of common stock, which, using the reported average sale price as a proxy, represents an equity position of roughly $5.8 million in the company.

Filing Facts

CIK

1806310

Ticker

TSHA

Form

4

Source Type

fda

Accession

0001665124-26-000013

Alert Tier

7